Therefore, piRNA was involved in regulating of cardiac hypertrophy, and the CHAPIR–METTL3–PARP10–NFATC4 signaling axis could serve as a therapeutic target for the cardiac hypertrophy and cardiac remodeling treatment. This evidence concerns the gene NFATC4 and cardiac hypertrophy.